Orthofix Medical Inc. Common Stock (DE)
OFIX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for OFIX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · OFIX
Orthofix Medical Inc. is a medical device company focused on spinal implants, biologics, enabling technologies, and limb reconstruction solutions, with a reported net loss of $15.8M on revenue of $210.9M for the quarter ended June 30, 2026.
Key risk: Competitive product obsolescence
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 17 clinical trials for Orthofix Medical Inc. Common Stock (DE).
Orthofix Medical Inc. is a medical device company focused on spinal implants, biologics, enabling technologies, and limb reconstruction solutions, with a reported net loss of $15.8M on revenue of $210.9M for the quarter ended June 30, 2026.
- Orthofix operates through two reporting segments: Global Spine and Global Limb Reconstruction [sec_mda · as of 2026-05-05].
- For the three months ended June 30, 2026, net sales were $210.9M, with a net loss of $15.8M [sec_mda · as of 2026-08-05].
- As of June 30, 2026, the company held cash & equivalents of $103.8M, shareholders' equity of $458.3M, and total debt of $12.9M [latest reported financials].
- The company's biologics portfolio is described as 'one of the most comprehensive biologics portfolios in both the demineralized bone matrix and cellular allograft market segments' [sec_mda · as of 2026-05-05].
- Adjusted EBITDA (non-GAAP) for Q2 2026 was $20.1M [sec_mda · as of 2026-08-05].
What works
- The company has a comprehensive biologics portfolio covering demineralized bone matrix and cellular allograft segments [sec_mda · as of 2026-05-05].
- Biologics segment 'stabilized and began to regain momentum, supported by focused commercial execution' [sec_mda · as of 2026-08-05].
- Gross profit margin improved to 71.0% of net sales in Q2 2026 from 68.7% in Q2 2025 [sec_mda · as of 2026-08-05].
What to weigh
- The company reported a net loss of $15.8M for Q2 2026 [sec_mda · as of 2026-08-05].
- Sales, general, and administrative expenses remain high at $138.0M for Q2 2026, representing 65.4% of net sales [sec_mda · as of 2026-08-05].
- The company faces risks from new product developments by competitors that could make its products non-competitive or obsolete [sec_mda · as of 2026-02-24].
- Clinical development is described as 'a lengthy and expensive process with an inherently uncertain outcome' [sec_mda · as of 2025-02-25].
From the filings
Quoted directly from source documents.
Biologics segment regained momentum in Q2 2026
“Biologics stabilized and began to regain momentum, supported by focused commercial execution.”
SEC MD&A · August 5, 2026
Company has a comprehensive biologics portfolio
“one of the most comprehensive biologics portfolios in both the demineralized bone matrix and cellular allograft market segments”
SEC MD&A · May 5, 2026
Net loss for Q2 2026 was $15.8 million
“Second quarter 2026 reported net loss of $(15.8) million”
SEC MD&A · August 5, 2026
Competitive risk from new product developments
“New product developments and improvements by our competitors could make our products or technologies non-competitive or obsolete.”
SEC MD&A · February 24, 2026
Risks & what to watch (4)›
Key risks
- Competitive product obsolescence — New product developments by competitors could make Orthofix's products non-competitive or obsolete [sec_mda · as of 2026-02-24].
- Clinical development uncertainty — Clinical development is lengthy and expensive with inherently uncertain outcomes; failure could materially affect results [sec_mda · as of 2025-02-25].
- Regulatory clearance risk — No guarantee that regulatory authorities will grant clearance or premarket approval for future products [sec_mda · as of 2026-02-24].
- Cyber and data security threats — Security breaches or cyber-attacks could compromise sensitive information and adversely affect business [sec_mda · as of 2026-02-24].
What to watch
- Continued momentum in the biologics segment and its impact on overall revenue growth [sec_mda · as of 2026-08-05].
- Trend in net losses and progress toward profitability, given the Q2 2026 net loss of $15.8M [sec_mda · as of 2026-08-05].
- Ability to manage high SG&A expenses, which were 65.4% of net sales in Q2 2026 [sec_mda · as of 2026-08-05].
- Regulatory outcomes for new product candidates and any competitive product launches [sec_mda · as of 2026-02-24].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Orthofix Medical Inc. Common Stock (DE) through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Orthofix Medical Inc. Common Stock (DE) facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
99.5 months
D/E 1.03 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
12 buys · 21 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
143
Total value held
$286.9M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 3,310,898 | $38.0M |
| paradigm capital management inc/ny | 3,304,899 | $37.9M |
| blackrock, inc. | 3,207,789 | $36.8M |
| armistice capital, llc | 2,700,000 | $31.0M |
| millennium management llc | 1,066,900 | $12.2M |
| geode capital management, llc | 938,885 | $10.8M |
| state street corp | 907,432 | $10.4M |
| dimensional fund advisors lp | 841,521 | $9.7M |
| ayal capital advisors ltd | 783,689 | $9.0M |
| philosophy capital management llc | 558,901 | $6.4M |
Showing top 10 of 143 institutional holders of Orthofix Medical Inc. Common Stock (DE). Open the full 13F history after sign-in.
Short Interest
as of May 12, 2026- % of float
- 3.5%
- Days to cover
- 5.3
- Shares short
- 1,237,366
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
OFIX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Orthofix Medical Inc. Common Stock (DE)?
Orthofix Medical Inc. is a medical device company focused on spinal implants, biologics, enabling technologies, and limb reconstruction solutions, with a reported net loss of $15.8M on revenue of $210.9M for the quarter ended June 30, 2026.
Who is the CEO of Orthofix Medical Inc. Common Stock (DE)?
Mr. Massimo Calafiore is the chief executive officer of Orthofix Medical Inc. Common Stock (DE) (OFIX).
Where is Orthofix Medical Inc. Common Stock (DE) headquartered?
Orthofix Medical Inc. Common Stock (DE) (OFIX) is headquartered in Lewisville, TX, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.